Sustainability has become a paramount concern in the biopharma industry, as evidenced by a recent comprehensive survey conducted by Cytiva and the Financial Times research unit, FT Longitude. This survey, involving over 800 executives from diverse global companies, reveals a growing commitment to
The global pharmaceutical industry is undergoing a transformative phase, driven by rapid advancements in technology, increasing demand for healthcare solutions, and strategic expansions by leading companies. Esteve Pharmaceuticals, a major player in the sector, is making headlines with its
In a significant move to improve data practices within the biopharmaceutical industry, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has partnered with the Open Applications Group (OAGi). This collaboration aims to overcome the prevalent issue of data
Novo Nordisk, a global leader in healthcare solutions for chronic diseases, has embarked on a transformative expansion project in Clayton, North Carolina. This unprecedented $6.8 billion investment aims to significantly ramp up the company's production capacity for injectable treatments, thereby
Biopharmaceuticals are in a critical transition phase where the mission to provide high-quality, effective drugs is increasingly converging with the demand for environmentally sustainable production methods. This balance requires the adoption of innovative technologies under the Industry 5.0
The seamless integration of technology into the fabric of scientific research has brought about a seminal shift in the analytical instrument industry. Key industry players have long recognized that innovation is not just a buzzword but the fundamental driver of growth and efficiency in the lab.
